[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

New China Drugs Markets Research Reports by CRI Now Available at MarketPublishers.com

19 Jun 2015 • by Natalie Aster

LONDON – TD The Market Publishers, Ltd. is happy to announce that new research studies on various Chinese drugs markets elaborated by China Research and Intelligence (CRI) have been added to its catalogue.

Investigation Report on China Imatinib Mesylate Market, 2010-2019. Annual sales of Imatinib Mesylate surpassed the CNY 530 million mark in 2014 in China, growing at a CAGR of over 40 percent over the period 2005-2014. The local market includes three players, with Novartis being a leading one. It holds a market share of 98 percent. The research report offers an in-depth analysis of the Imatinib Mesylate market in China. The study contains a detailed overview of the marketplace and estimates a size of the market, delves deep into the competitive environment and comprises sales statistics…

Investigation Report on China Insulin Detemir Market, 2010-2019. As of 2010, annual sales of Insulin Detemir amounted to CNY 3 million in Chima. The sales grew at a swift pace over the period 2010-2014, with a CAGR reaching approximately 135 percent. In 2014, the sales stood at CNY 68 million. At present, the local market is ruled by Novo Nordisk. The research study provides an up-close look at the performance of the Chinese market for Insulin Detemir. The report offers a thorough overview of the marketplace, investigates the competitive landscape, casts light on price trends, …

Investigation Report on China Linezolid Market, 2010-2019. Sales of Linezolid have not been stable in China over the past few years. For instance, the sales stood at CNY 113 million in 2010, while they were no more than CNY 93 million in 2014. Pfizer is currently the most prominent market player, with its market share being around 70 percent. The research report is a source of unique information on the Chinese market for Linezolid. The report offers an insightful overview of the market, unveils historical data related to the marketplace and forecasts market development trends…

Investigation Report on China Meropenam Market, 2010-2019. Currently, there are more than 25 companies producing Meropenam in China. As of 2014, the sales value of Meropenam amounted to about CNY 970 million, growing at a CAGR of more than 27 percent over the period 2005-2014. The report provides a comprehensive guide to the Meropenam market in China. The research study offers an all-round overview of the marketplace. It estimates a market size and limelights the competitive landscape. It comprises profiles of top players and data on pricing. Future market outlook is available in the report too…

More new studies by the publisher can be found at CRI page


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected] 

Analytics & News

Weekly Digest